Bullish case
$198 to $208
More likely if Keytruda Qlex and earlier-stage oncology use extend durability, Winrevair and new launches compound, Gardasil stabilizes, late-stage assets hit, and investors value MRK near a high-teens earnings multiple.
Merck & Co., Inc. research snapshot
MRK AI Stock Analysis
MRK AI stock analysis currently reads Merck & Co., Inc. as a high-quality biopharma company with deep oncology scale, strong cash generation, and a large but concentrated Keytruda franchise. At the July 8, 2026 data cutoff, MRK traded near $128.86 with an implied market capitalization of about $318.26 billion. The positive case depends on Keytruda durability, Winrevair growth, new launches, and pipeline execution. The risk case centers on the 2028 Keytruda loss of exclusivity, Gardasil pressure, acquisition charges, and valuation sensitivity. This page is informational research, not investment advice.
Current price
$128.86
Market cap
$318.26 billion
AI score
72 / 100
Rating
High-quality pharma franchise with patent-cliff risk
Trend status
Constructive trend near 52-week highs
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Merck has long public filings, detailed annual and quarterly disclosures, liquid market data, broad analyst coverage, and multiple independent financial data providers.
- bias Check
- The main AI bias risk is over-weighting the visible quality of Keytruda, oncology scale, and dividend record while under-weighting patent-cliff timing, pipeline substitution risk, Gardasil volatility, debt-funded acquisitions, and single-franchise concentration.
- ai Confidence
- High for reported sales, share count, balance sheet, market cap math, and technical indicators. Medium for forward valuation because post-2028 oncology revenue, trial outcomes, regulatory timing, and acquisition payoffs can change quickly.
- investment Certainty
- Medium. The business is strong, but investment certainty is lower than data confidence because Merck must replace a very large Keytruda profit pool over the next several years.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Merck sells prescription medicines, vaccines, and animal health products, with Keytruda and oncology forming the largest profit engine. | High |
| Moat | The moat comes from patents, clinical evidence, regulatory approvals, physician familiarity, payer access, manufacturing scale, and a global oncology commercial footprint. | High |
| Management | Chairman and CEO Robert M. Davis is using business development, pipeline investment, and reorganization to prepare for Keytruda exclusivity pressure. | Medium-high |
| Financial trend | FY2025 sales rose 1.3% to $65.011 billion, and Q1 2026 sales rose 5% to $16.286 billion, but Q1 GAAP EPS turned negative because of a Cidara acquisition charge. | High |
| Valuation | At $128.86, MRK traded near 36.3x TTM GAAP EPS, 22.6x TTM free cash flow per share, 6.9x book value, and a 2.6% dividend yield. | Medium-high |
| Technical trend | The stock was above major moving averages and within roughly 1% of its 52-week high, which supports momentum but leaves little room for weak pipeline news. | Medium |
| Risk level | The biggest risks are Keytruda loss of exclusivity, Gardasil demand weakness, clinical trial failure, regulatory pressure, legal disputes, and acquisition integration. | Medium-high |
| AI confidence | High for descriptive research and arithmetic checks. Lower for exact stock outcomes because healthcare stocks can reprice around trial data, FDA decisions, patents, guidance, and deal charges. | High data confidence |
| Investment certainty | Medium certainty. Merck is a durable company, but a buy decision depends on whether the pipeline can offset Keytruda concentration at the current valuation. | Medium |
MRK AI stock forecast
MRK AI Stock Forecast Scenarios
The MRK AI stock forecast uses scenario math around the $128.86 quote and FY2025 non-GAAP EPS of $8.98 as a normalized earnings base. The audited three-year framework produced a bearish area near $77, a base area near $147, and a bullish area near $204 before dividends.
Base case
$142 to $152
More likely if normalized EPS grows in the low single digits, Keytruda erosion is manageable, business development partly fills the gap, and the market applies a mid-teens earnings multiple.
Bearish case
$72 to $82
More likely if Keytruda losses accelerate after exclusivity changes, Gardasil remains weak, pipeline launches disappoint, acquisition charges dilute returns, or the market compresses MRK toward a low-teens earnings multiple.
MRK AI technical analysis
MRK AI Technical Analysis
MRK AI technical analysis was constructive as of the July 8, 2026 cutoff. MRK was trading near $128.86, below the $130.29 52-week high but above Investing.com moving average snapshots near $127.79 for the 50-day average and $120.67 for the 200-day average. Momentum was positive, with third-party RSI readings around the low 60s.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $128.86 | Quote snapshot used for market cap math at the July 8, 2026 cutoff. |
| Near support | $127 to $129 | Recent trading clustered around the prior close and the 50-day moving average zone. |
| Near resistance | $130 to $131 | The 52-week high near $130.29 makes this the first resistance area to watch. |
| 50-day moving average | About $127.79 | Investing.com listed the 50-day moving average as a buy signal near the cutoff. |
| 200-day moving average | About $120.67 | The price remained above the 200-day moving average, supporting the longer trend. |
| Momentum | 14-day RSI around 62.5 | GuruFocus listed positive but not extreme momentum, while other technical services also showed a constructive setup. |
| Volume | About 8.7 million recent shares | MarketWatch reported July 7 volume below the 50-day average, so breakout confirmation still needs volume support. |
| Volatility | Moderate large-cap pharma volatility | Expect larger moves around earnings, FDA decisions, trial results, patent news, litigation, and acquisition updates. |
| Invalidation | Close below $127, then $120 | A decisive break below the 50-day area would weaken the short-term setup. A break below the 200-day area would be a larger trend warning. |
MRK AI trading strategy
MRK AI Trading Strategy Framework
The MRK AI trading strategy is a rules-based research framework for a large-cap biopharma stock trading near resistance with material patent-cycle risk. It is not personal advice and should be paired with live quotes, filings, event calendars, and position sizing rules.
Trend-following setup
Watch for MRK to hold above the $127 to $129 support area and clear the $130 to $131 resistance zone with volume above the recent average.
A close below $127 or a failed breakout after pipeline or earnings news should invalidate the short-term setup.
Mean-reversion setup
If MRK pulls back toward the 200-day moving average without new Keytruda, Gardasil, guidance, or trial-data damage, compare the selloff with normalized earnings power and free cash flow.
Do not average down without a defined loss limit because patent and regulatory events can turn a technical support level into a thesis break.
Fundamental monitor
Track Keytruda and Keytruda Qlex, Winrevair, Gardasil, Animal Health, Terns and Cidara integration, late-stage oncology assets, cash conversion, debt, dividend coverage, and 2026 guidance.
Reduce confidence if growth depends mainly on multiple expansion or acquisitions rather than durable product-level sales, approvals, and cash conversion.
Investment research summary
Four-master Research Compression
Business essence
Merck converts scientific research, regulatory approval, clinical evidence, physician trust, and global distribution into recurring revenue from patented medicines, vaccines, and animal health products.
Moat
The moat is strongest in oncology where patents, trial data, approved indications, prescriber familiarity, manufacturing know-how, and payer access reinforce each other. It narrows when exclusivity expires or a rival offers better efficacy, safety, convenience, or cost.
Munger risk inversion
The thesis fails if Keytruda revenue falls faster than replacement products scale, Gardasil remains pressured, clinical assets disappoint, acquisitions destroy capital, or regulation and pricing pressure reduce margins.
Management
Robert M. Davis became CEO in 2021 and chairman in 2022. Management is pushing business development, reorganization, and pipeline investment to reduce dependence on Keytruda before the largest patent-cycle test arrives.
Industry trend
Biopharma benefits from aging demographics, oncology innovation, cardiometabolic demand, vaccines, and animal health needs, but the industry faces patent cliffs, payer pressure, political scrutiny, litigation, and binary clinical outcomes.
Valuation and margin of safety
MRK is not priced as a distressed patent-cliff stock, but it is also below many faster-growth healthcare peers. Margin of safety depends on whether normalized earnings and free cash flow can hold through the Keytruda transition.
Source-backed data
MRK Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MRK price | $128.86 | TradingView and MarketWatch quote snapshots | July 8, 2026 |
| Market capitalization | $318.26 billion, verified as $128.86 x 2.469824415 billion shares | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 2.469824415 billion as of April 30, 2026, cross-checked against StockAnalysis 2.47 billion | Merck Q1 2026 Form 10-Q and StockAnalysis | July 8, 2026 |
| FY2025 reported sales | $65.011 billion | Merck 2025 Form 10-K, Macrotrends, and StockAnalysis | July 8, 2026 |
| FY2025 net income attributable to Merck | $18.254 billion | Merck 2025 Form 10-K, Macrotrends, and StockAnalysis | July 8, 2026 |
| FY2025 free cash flow | About $12.4 billion | StockTitan and Merck 2025 cash flow statement | July 8, 2026 |
| Q1 2026 cash and short-term investments | $5.702 billion | Merck Q1 2026 Form 10-Q, StockAnalysis, and MarketBeat | July 8, 2026 |
| Q1 2026 long-term debt | $46.673 billion | Merck Q1 2026 Form 10-Q and StockAnalysis balance sheet | July 8, 2026 |
| FY2025 segment sales | $58.142 billion Pharmaceutical and $6.354 billion Animal Health | Merck 2025 Form 10-K segment table | July 8, 2026 |
| Q1 2026 sales and EPS | $16.286 billion sales, GAAP loss per share of $1.72, and non-GAAP loss per share of $1.28 including a $3.62 Cidara charge | Merck Q1 2026 earnings release and Form 10-Q | July 8, 2026 |
| Updated 2026 sales guidance | $65.8 billion to $67.0 billion | Merck Q1 2026 earnings release | July 8, 2026 |
| Technical indicators | 50-day moving average near $127.79, 200-day moving average near $120.67, and RSI around 62.5 | Investing.com and GuruFocus technical snapshots | July 8, 2026 |
Frequently Asked Questions
Compare JNJ AI stock analysisRead ABBV AI stock forecastReview LLY AI technical analysisExplore Pineify AI Stock Picker
This MRK AI stock analysis is an informational research tool only. It is not investment advice, a recommendation to buy or sell Merck & Co., Inc., or a guarantee of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if fundamentals, valuation, patents, clinical data, regulation, or market conditions change.